Sign inJoin waitlistJoin the waitlist

Jeremie Calais

Director, Theranostics Program · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · ·

History

UCLA David Geffen School of Medicine/UCLA Medical Center
Present
Department of Nuclear Medicine and Theranostics · UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA David Geffen School of Medicine/UCLA Medical Center
Present

Université Paris Cité
2015–2016
University of Rouen School of Medicine
2014–2015
University of Rouen School of Medicine
2011–2014
University Paris-Saclay, Paris, France
Faculty of Medicine Xavier Bichat, University of Paris
2006–2010

Research

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
JAMA Oncology · 2019 · 672 citations
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Journal of Nuclear Medicine · 2018 · 515 citations
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging…
The Lancet Oncology · 2019 · First of 22 authors · Corresponding · 396 citations

Johannes Czernin
118 papers
Thomas Hope
51 papers · 1 as a fellow
Matthew Rettig
46 papers
Andrei Gafita
42 papers · 17 as a resident
Amar Kishan
41 papers · 2 as a resident
Robert Reiter
37 papers
Nicholas Nickols
29 papers
MB
Matthias Benz
26 papers
Martin Allen-Auerbach
23 papers
Michael Steinberg
19 papers
Luca Valle
17 papers · 5 as a resident
Vishnu Murthy
14 papers · 5 as a resident

Clinical trials

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Principal investigator · Active not recruiting · Phase 1
Jonsson Comprehensive Cancer Center
2025–2027
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Principal investigator · Recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2024–2028
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Principal investigator · Recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2024–2028
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Principal investigator · Active not recruiting · Early phase 1
Jonsson Comprehensive Cancer Center
2022–2027